Medicine summary - citalopram (to end January 2009)

Size: px
Start display at page:

Download "Medicine summary - citalopram (to end January 2009)"

Transcription

1 Blood and lymphatic system disorders Iron deficiency anaemia Anaemia Pancytopenia Thrombocytopenia Lymphadenopathy Eosinophilia Leukocytosis Leukopenia Neutropenia Blood and lymphatic system disorders Cardiac disorders Atrioventricular block Arrhythmia Bradycardia Extrasystoles Tachycardia Arrhythmia supraventricular Sick sinus syndrome Sinus bradycardia Supraventricular tachycardia Cardiac arrest Torsade de pointes Ventricular tachycardia Cyanosis Palpitations Myocardial infarction Myocardial ischaemia Cardiomyopathy Cardiac disorders Congenital, familial and genetic disorders Ventricular hypoplasia Ventricular septal defect Fallot's tetralogy Congenital anomaly Congenital, familial and genetic disorders Ear and labyrinth disorders Ear pain Deafness unilateral Hearing impaired Hyperacusis Tinnitus Vertigo Ear and labyrinth disorders Endocrine disorders Hyperprolactinaemia /09/ :31:03 AM

2 Endocrine disorders Inappropriate antidiuretic hormone secretion Endocrine disorders Eye disorders Eye pain Eye swelling Glaucoma Conjunctival haemorrhage Keratitis Blepharospasm Strabismus Mydriasis Photophobia Accommodation disorder Diplopia Photopsia Vision blurred Visual impairment Eye disorders Gastrointestinal disorders Abdominal hernia Anorectal disorder Tooth disorder Toothache Tooth discolouration Gingivitis Gingival bleeding Pancreatitis Rectal haemorrhage Gastrointestinal haemorrhage Haematemesis Melaena Colitis Gastritis Crohn's disease Diarrhoea Constipation Gastrointestinal motility disorder Ileus paralytic Dyspepsia Eructation Abdominal distension Flatulence Abdominal pain Abdominal pain upper /09/ :31:03 AM

3 Gastrointestinal disorders Abdominal discomfort General disorders and administration site conditions Breath odour Dysphagia Nausea Vomiting Intestinal obstruction Duodenal ulcer Lip oedema Lip swelling Hypoaesthesia oral Oral discomfort Mouth ulceration Dry mouth Salivary hypersecretion Glossitis Swollen tongue Gastrointestinal disorders Hypothermia Pyrexia Sudden death Asthenia Fatigue Malaise Gait disturbance Condition aggravated Influenza like illness Irritability Swelling Face oedema Generalised oedema Oedema Oedema peripheral Chest pain Pain Chest discomfort Chills Feeling abnormal Feeling cold Feeling hot Feeling jittery Thirst /09/ :31:03 AM

4 General disorders and administration site conditions Drug interaction Drug ineffective Drug tolerance increased Therapeutic response decreased Therapeutic response unexpected Drug withdrawal syndrome Drug withdrawal syndrome neonatal General disorders and administration site conditions Hepatobiliary disorders Vanishing bile duct syndrome Hepatitis cholestatic Jaundice Jaundice cholestatic Liver disorder Hepatic function abnormal Hepatic failure Hepatomegaly Hepatitis Hepatobiliary disorders Immune system disorders Hypersensitivity Immune system disorders Infections and infestations Vaginal infection Infection Bronchitis Pneumonia Rash pustular Pharyngitis Rhinitis Sinusitis Upper respiratory tract infection Herpes simplex Influenza Infections and infestations Injury, poisoning and procedural complications Drug exposure during pregnancy Fall Contusion Intentional overdose Overdose Injury, poisoning and procedural complications Investigations Electrocardiogram QT prolonged Electrocardiogram T wave inversion /09/ :31:03 AM

5 Investigations Electrocardiogram abnormal Blood pressure increased Blood creatine phosphokinase increased Prothrombin time prolonged Gamma-glutamyltransferase increased Liver function test abnormal Oxygen saturation decreased Blood glucose decreased Blood glucose increased Electroencephalogram abnormal Apgar score low Respiratory rate increased Weight decreased Weight increased C-reactive protein increased Blood creatinine increased Drug level decreased Drug level increased Investigations Metabolism and nutrition disorders Decreased appetite Musculoskeletal and connective tissue disorders Tetany Hypomagnesaemia Electrolyte imbalance Polydipsia Hyperkalaemia Hypokalaemia Hypernatraemia Hyponatraemia Dehydration Alcohol intolerance Diabetes mellitus Hyperinsulinaemia Hypoglycaemia Hypoglycaemia neonatal Metabolism and nutrition disorders Exostosis Bone pain Sjogren's syndrome Arthralgia Joint stiffness Myalgia Muscle spasms /09/ :31:03 AM

6 Musculoskeletal and connective tissue disorders Neoplasms benign, malignant and unspecified (incl cysts and polyps) Muscle twitching Muscle rigidity Trismus Muscular weakness Rhabdomyolysis Musculoskeletal stiffness Back pain Pain in extremity Musculoskeletal and connective tissue disorders Langerhans' cell granulomatosis Lymphoma Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nervous system disorders Cerebral haemorrhage Cerebrovascular disorder Drug withdrawal headache Headache Migraine Brain oedema Dementia Amnesia Memory impairment Cognitive disorder Disturbance in attention Chorea Akathisia Bradykinesia Clumsiness Dyskinesia Extrapyramidal disorder Hyperkinesia Hypokinesia Tardive dyskinesia Dystonia Opisthotonus Paresis Tremor Hyperreflexia Ataxia Balance disorder Coordination abnormal /09/ :31:03 AM

7 Nervous system disorders Nystagmus Pregnancy, puerperium and perinatal conditions Coma Coma hepatic Aphasia Consciousness fluctuating Depressed level of consciousness Lethargy Loss of consciousness Sedation Somnolence Syncope Dizziness Myoclonus Crying Burning sensation Formication Paraesthesia Ageusia Dysgeusia Hypoaesthesia Restless legs syndrome Sensory disturbance Dysarthria Speech disorder Hypertonia Neuroleptic malignant syndrome Serotonin syndrome Muscle contractions involuntary Myasthenic syndrome Neuropathy peripheral Grand mal convulsion Convulsion Epilepsy Nervous system disorders Intra-uterine death Stillbirth Foetal cardiac disorder Foetal disorder Foetal distress syndrome Pre-eclampsia Neonatal disorder Meconium stain /09/ :31:03 AM

8 Pregnancy, puerperium and perinatal conditions Pregnancy, puerperium and perinatal conditions Psychiatric disorders Agitation Agitation neonatal Anxiety Nervousness Tension Fear Panic attack Panic disorder Neurosis Restlessness Automatism Bruxism Screaming Confusional state Disorientation Delirium Depression Depersonalisation Dissociation Delusion Hallucination Hallucination, auditory Hallucination, visual Thinking abnormal Eating disorder Hypomania Mania Affect lability Anger Euphoric mood Mood altered Mood swings Aggression Homicidal ideation Indifference Paranoia Violence-related symptom Abnormal behaviour Hypervigilance Mental disorder /09/ :31:03 AM

9 Psychiatric disorders Withdrawal syndrome Acute psychosis Psychotic disorder Anorgasmia Libido decreased Insomnia Sleep attacks Abnormal dreams Abnormal sleep-related event Nightmare Sleep disorder Completed suicide Intentional self-injury Self injurious behaviour Self-injurious ideation Suicidal ideation Suicide attempt Psychiatric disorders Renal and urinary disorders Tubulointerstitial nephritis Anuria Renal failure Renal failure acute Renal impairment Renal tubular necrosis Urethral disorder Dysuria Pollakiuria Urethral pain Urinary hesitation Urinary incontinence Urinary retention Chromaturia Haematuria Nocturia Polyuria Renal pain Renal and urinary disorders Reproductive system and breast disorders Breast enlargement Gynaecomastia Breast pain Galactorrhoea Suppressed lactation /09/ :31:03 AM

10 Reproductive system and breast disorders Premenstrual syndrome Amenorrhoea Penile size reduced Penis disorder Genital ulceration Perineal pain Ejaculation delayed Ejaculation disorder Ejaculation failure Erectile dysfunction Priapism Sexual dysfunction Uterine haemorrhage Vaginal haemorrhage Vulval ulceration Vulval erythema Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Asthma Interstitial lung disease Pulmonary fibrosis Pulmonary hypertension Pulmonary embolism Apnoea Dyspnoea Hyperventilation Hypoventilation Respiratory depression Hypoxia Cough Sputum increased Hiccups Respiratory failure Aspiration Respiratory disorder Dysphonia Sneezing Snoring Throat irritation Yawning Stridor Nasal congestion Epistaxis /09/ :31:03 AM

11 Respiratory, thoracic and mediastinal disorders Nasal dryness Pharyngeal oedema Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Angioedema Periorbital oedema Urticaria Mechanical urticaria Blister Dry skin Skin burning sensation Skin discolouration Dermatitis Drug eruption Erythema Rash erythematous Dermatitis exfoliative Exfoliative rash Skin exfoliation Lichen sclerosus Rash papular Photosensitivity reaction Pruritus Rash pruritic Psoriasis Fixed eruption Rash Rash generalised Rash macular Rash maculo-papular Erythema nodosum Acne Alopecia Cold sweat Hyperhidrosis Nail disorder Henoch-Schonlein purpura Increased tendency to bruise Purpura Skin and subcutaneous tissue disorders Social circumstances Walking disability Social circumstances /09/ :31:03 AM

12 Surgical and medical procedures Abortion induced Drug therapy changed Therapy regimen changed Surgical and medical procedures Vascular disorders Peripheral ischaemia Circulatory collapse Hypotension Orthostatic hypotension Deep vein thrombosis Flushing Hot flush Pallor Hypertension Arteritis Vasculitis Vascular disorders /09/ :31:03 AM

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia. ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders

More information

Medicine summary - Antipsychotics- chlorpromazine

Medicine summary - Antipsychotics- chlorpromazine 591 21 241 Blood and lymphatic system disorders Anaemia 3 0 0 Aplastic anaemia 3 1 0 Pancytopenia 2 1 1 Thrombocytopenia 6 1 1 Thrombocytosis 1 0 0 Lymphadenopathy 3 1 1 Eosinophilia 5 0 0 Leukocytosis

More information

Medicine summary - Antipsychotics- haloperidol

Medicine summary - Antipsychotics- haloperidol 748 22 330 Blood and lymphatic system disorders Anaemia 2 0 0 Bone marrow failure 1 0 0 Pancytopenia 4 0 1 Haemolytic anaemia 1 0 0 Thrombocytopenia 2 0 0 Lymphadenopathy 1 0 0 Splenomegaly 2 0 0 Eosinophilia

More information

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic

More information

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015 1 2015-023780 2015-023788 2015-023805 2015-023819 2015-023820 2015-023821 Injection site swelling Transient immobility Abdominal pain Visual acuity reduced Chronic fatigue syndrome Mental disorder Pallor

More information

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine Suspected Adverse Reaction Analysis CERVARIX Human papillomavirus (HPV) vaccine 2 May 2009 This report summarises the adverse reactions suspected to have been caused by Cervarix human papillomavirus (HPV)

More information

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014 - 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases

More information

Case Series Drug Analysis Print Name: Isotretinoin

Case Series Drug Analysis Print Name: Isotretinoin Report Run Date: 30-Dec-2013 Data Lock Date: 27-Dec-2013 23:09:23 Earliest Reaction Date: 12-Jun-1997 MedDRA Version: MedDRA 16.1 Isotretinoin: No description provided. Report Run Date: 30-Dec-2013, Page

More information

Continence PGD - Oxybutynin 5mg Modified Release

Continence PGD - Oxybutynin 5mg Modified Release Continence PGD - Oxybutynin 5mg Modified Release Patient group direction for the supply of Oxybutynin Lyrinel XL 5mg and 10mg tablets, maximum dose of 20mg/day to patients suffering from urinary frequency,

More information

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg UK/H/PSUR/0027/002 Date of FAR:

Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg UK/H/PSUR/0027/002 Date of FAR: M0BCore Safety Profile Active substance: Glatiramer Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg P-RMS: UK/H/PSUR/0027/002 Date of FAR: 20.03.2013 4.2 Posology

More information

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE The CSM Working Group on Patient Information recognises that users may not be familiar with the terms used in patient information leaflets to describe unwanted

More information

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013 CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR: Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension

More information

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring ENCePP Plenary meeting Xavier Kurz 8 June 20 An agency of the European Union Contents 1. Safety database at time of authorisation

More information

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015 Page 1 of 6 Adverse (s) Date Outcome 2014-019844 04/03/2014 13 Years Prophylaxis GARDASIL 04/12/2013 Nausea 04/12/2013 06/12/2013 Headache 04/12/2013 06/12/2013 Vomiting 04/12/2013 06/12/2013 Asthenia

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary and Mandatory Reports on 5-Hour Energy,

More information

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: 0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR: Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 2 medicines between 01/01/2000 18/10/2017: Invokana (Canagliflozin) Not specified (Canagliflozin) Commonwealth of Australia

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Medical History Form

Medical History Form General: Medical History Form 1. Chief Complaint: What are the main health concerns you wish to address? 2. Current and Past Treatment: Have you received treatment for these problems? Yes No, if yes, which:

More information

Headache Follow-up Visit Form

Headache Follow-up Visit Form !1 Headache Follow-up Visit Form We will be unable to see you unless this form is completely filled out. We appreciate your thoroughness. Name DOB Age Today s Date Referring doctor: Primary doctor: Neurologist:

More information

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With

More information

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber. Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient

More information

Pregabalin (Prepentin)

Pregabalin (Prepentin) Korea United Pharm. Inc. Pregabalin (Prepentin) 75 mg, 150 mg CAPSULE Anticonvulsant Manufactured by: KOREA UNITED PHARM. INC. Imported/Distributed by: MACROPHARMA CORPORATION GENERIC NAME PREGABALIN IUPAC

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR: Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is

More information

Each hard capsule contains 25 mg, 50 mg, 75 mg, 100 mg or 150 mg of pregabalin.

Each hard capsule contains 25 mg, 50 mg, 75 mg, 100 mg or 150 mg of pregabalin. Pfizer Laboratories (Pty) Ltd Page 1 of 13 SCHEDULING STATUS: S5 PROPRIETARY NAME AND DOSAGE FORM: LYRICA 25 mg capsule LYRICA 50 mg capsule LYRICA 75 mg capsule LYRICA 100 mg capsule LYRICA 150 mg capsule

More information

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: 0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:

More information

Core Safety Profile Triptorelin 1-month/3-month formulation ATC-code: L02A E 04 March 2010

Core Safety Profile Triptorelin 1-month/3-month formulation ATC-code: L02A E 04 March 2010 Core Safety Profile Triptorelin 1-month/3-month formulation ATC-code: L02A E 04 March 2010 4.3 Contraindications Hypersensitivity to GnRH, its analogues or any other component of the medicinal product

More information

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.) Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections

More information

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425) IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:

More information

NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C.

NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C. NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C. Past Medical History AIDS/HIV disease Anemia Asthma Bronchitis Cancer Date of last Chest X-ray Diabetes Mellitus, Type I Diabetes Mellitus,

More information

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR: M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered

More information

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR: 0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013

More information

Nilotinib AEs (adverse events) in CML population:

Nilotinib AEs (adverse events) in CML population: Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have

More information

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash - Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

GLUCOSE TESTING-BLOOD

GLUCOSE TESTING-BLOOD 648.83 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, ANTEPARTUM CONDITION OR 648.84 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, POSTPARTUM

More information

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care Page 1 of 7 Patient Demographics First Name* Last Name* Date Of Birth* Home Phone* Mobile Phone Phone Gender* Email Preferred Communication Street Address 1* Street Addresss 2 Zip* City* State* Emergency

More information

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least

More information

Episodes of Care Risk Adjustment

Episodes of Care Risk Adjustment Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous

More information

Treatment of Alzheimer s disease

Treatment of Alzheimer s disease NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Treatment of Alzheimer s disease Acetylcholinesterase

More information

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1 Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma

More information

Case Series Drug Analysis Print Name: Gardasil

Case Series Drug Analysis Print Name: Gardasil Report Run Date: 12-Mar-2015 Data Lock Date: 11-Mar-2015 19:00:07 Earliest Reaction Date: 29-Nov-2006 MedDRA Version: MedDRA 17.1 Gardasil: Gardasil Drug Analysis Print Report Run Date: 12-Mar-2015, Page

More information

Supplementary materials for:

Supplementary materials for: Supplementary materials for: Cecil E, Bottle A, Sharland M, Saxena S. Impact of UK primary care policy reforms on short-stay unplanned hospital admissions for children with primary care-sensitive conditions.

More information

Joseph S. Weiner, MD, PC Patient History Form

Joseph S. Weiner, MD, PC Patient History Form Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR: M0BCore Safety Profile Active substance: Pantoprazole Pharmaceutical form(s)/strength: several forms and strength P-RMS: DE/H/PSUR/0039/001 Date of FAR: 05.12.2013 Annex I : CSP 4.3 Contraindications Hypersensitivity

More information

1.1. An overview of reports on agomelatine

1.1. An overview of reports on agomelatine 1.1. An overview of reports on agomelatine Introduction Agomelatine (Valdoxan ) was registered for the European market on February 19th 2009 and is indicated for treatment of major depressive episodes

More information

T- Timing- concise vs. complete and thorough, depending on need of presenter and audience. E- Elicit- ask for feedback- more information needed? Less?

T- Timing- concise vs. complete and thorough, depending on need of presenter and audience. E- Elicit- ask for feedback- more information needed? Less? Review of STAGE presentation framework (from umass.macy.edu, revised Alicia Monroe, MD from 2005 STFM) S- style organization, sequencing adequate to build a case for your diagnosis or a story T- Timing-

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration

More information

EVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002)

EVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002) Acne Acrodermatitis Enteropathica Adrenal Support Age Related Cognitive Decline Alcoholism/Alcohol Withdrawal Alzheimer's Disease Amenorrhoea Anaemia Angina Anorexia Nervosa Anxiety Asthma Atherosclerosis

More information

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes.

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. Name: DOB: PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. TOBACCO USE: Quit Date Cigarettes Packs/Day Number of years smoked Pipe/Cigar Smokeless Tobacco Electronic or E-cigarette Secondhand

More information

Initial Consultation

Initial Consultation Today s Date: Initial Consultation Thank you for choosing Apollo Health and Wellness. Please take your time to fill out this form. It will help us to concentrate on areas of your health that need attention

More information

2014 NATIONAL COVERAGE DETERMINATION (NCD) CPT CODE(S): 84436, 84439, 84443, THYROID TESTING DESCRIPTION

2014 NATIONAL COVERAGE DETERMINATION (NCD) CPT CODE(S): 84436, 84439, 84443, THYROID TESTING DESCRIPTION 017.50-017.56 Tuberculosis of the thyroid gland 183.0 Malignant neoplasm of ovary 193 Malignant neoplasm of thyroid gland 194.8 Malignant neoplasm of other endocrine glands and related structures 198.89

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT LYRICA 25 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 25 mg of pregabalin. For excipients,

More information

MYLAN-RIVASTIGMINE PATCH 5 Rivastigmine Transdermal Patch Each patch of 5 cm 2 contains 9 mg rivastigmine base, in vivo release rate of 4.6 mg/24 h.

MYLAN-RIVASTIGMINE PATCH 5 Rivastigmine Transdermal Patch Each patch of 5 cm 2 contains 9 mg rivastigmine base, in vivo release rate of 4.6 mg/24 h. PRODUCT MONOGRAPH Pr MYLAN-RIVASTIGMINE PATCH 5 Rivastigmine Transdermal Patch Each patch of 5 cm 2 contains 9 mg rivastigmine base, in vivo release rate of 4.6 mg/24 h. Pr MYLAN-RIVASTIGMINE PATCH 10

More information

Complete the CE Checklist for Customized Symptoms. Page 1 of 6

Complete the CE Checklist for Customized Symptoms. Page 1 of 6 Progress Tracking Complete the CE Checklist for Customized Symptoms Page 1 of 6 Generic Positive Symptom Tracking Concentration Quality Of Sleep Motivation/Energy Patience Short Term Memory Appetite Positive

More information

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including: Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lind M, Polonsky W, Hirsch IB, et al. Effect of continuous glucose monitoring vs conventional therapy on glycemic control among patients type 1 diabetes treated multiple daily

More information

Drugs used in obstetrics

Drugs used in obstetrics Drugs used in obstetrics Drugs used in obstetrics Drugs may be used to modify uterine contractions. These include oxytocic drugs used to stimulate uterine contractions both in induction of labour and to

More information

PROFESSIONAL INFORMATION

PROFESSIONAL INFORMATION SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: DEMAZIN NS REPETABS COMPOSITION: Active Ingredients: Each DEMAZIN NS REPETAB contains 5 mg loratadine (micronised) in the tablet coating and 120

More information

Essential Wellness Of Illinois, LLC Health History Questionnaire Christine A. Renz L.Ac., Dipl OM, MSTOM

Essential Wellness Of Illinois, LLC Health History Questionnaire Christine A. Renz L.Ac., Dipl OM, MSTOM Name Date Address City State Zip Home Phone Cell Fax Email Emergency Contact Emergency Number Date of Birth Age Sex Height Weight Lbs Marital Status Occupation Who referred you to this office? Name of

More information

Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg

Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg 4.2 Posology and method of administration Children and adolescents Chlorprothixene is not recommended for use in children

More information

Package leaflet: Information for the user. Pregabalin Kern Pharma 75 mg hard capsules

Package leaflet: Information for the user. Pregabalin Kern Pharma 75 mg hard capsules Package leaflet: Information for the user Pregabalin Kern Pharma 75 mg hard capsules Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

UK Suspected Adverse Drug Reaction (ADR) Analysis

UK Suspected Adverse Drug Reaction (ADR) Analysis UK Suspected Adverse Drug Reaction (ADR) Analysis Influenza antivirals - oseltamivir (Tamiflu) and zanamivir (Relenza) 26 th November 2009 This report summarises all UK reports of suspected adverse drug

More information

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This

More information

Scottsdale Family Health

Scottsdale Family Health Please list pharmacy you would like us to use for your medications. Pharmacy Phone Number Fax Number Since your last visit: 1. Have you been diagnosed with any new medical conditions? Yes No If Yes (give

More information

P-RMS: FR/H/PSUR/0036/001

P-RMS: FR/H/PSUR/0036/001 Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,

More information

Sick Call Screener Course

Sick Call Screener Course Sick Call Screener Course SOAP Note (1.3) 1.3-2-1 Enabling Objective 1.5 Document a patient encounter 1.3-2-2 SOAP Note Standard for documentation Designed to allow easy reference for follow-up care. (U.S.

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole

More information

Buserelin Non European. European Economic Area

Buserelin Non European. European Economic Area Blood Card Cong Ear Endo Eye Non Anaemia 2 1 3 Aplastic anaemia 0 2 2 Eosinophilia 0 1 1 Haemolysis 1 0 1 Haemorrhagic disorder 0 1 1 Leukopenia 1 2 3 Thrombocytopenia 0 10 10 Angina pectoris 0 2 2 Arrhythmia

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR: Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011

More information

Charles Khouri, PharmD; Marion Lepelley, PharmD; Matthieu Roustit, PharmD; François Montastruc, MD; Marc Humbert, MD; and Jean-Luc Cracowski, MD

Charles Khouri, PharmD; Marion Lepelley, PharmD; Matthieu Roustit, PharmD; François Montastruc, MD; Marc Humbert, MD; and Jean-Luc Cracowski, MD Online Supplement Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis

More information

patient group direction

patient group direction CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

1.1. An overview of reports on sitagliptin

1.1. An overview of reports on sitagliptin 1.1. An overview of reports on Introduction Sitagliptin (Januvia ) was registered for the European marked on March 21 st 27 with the Netherlands as rapporteur. It is indicated as treatment of for patients

More information

Package leaflet: Information for the user. LETROKS, 2,5 mg, film-coated tablets Letrozolum

Package leaflet: Information for the user. LETROKS, 2,5 mg, film-coated tablets Letrozolum Package leaflet: Information for the user LETROKS, 2,5 mg, film-coated tablets Letrozolum Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Block GA, Bushinsky DA, Cunningham J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism:

More information

Patient Intake Form. Name: Date of Birth: Social Security No.: Address: City: State: Zip:

Patient Intake Form. Name: Date of Birth: Social Security No.: Address: City: State: Zip: Patient Intake Form Name: Date of Birth: Social Security No.: Address: City: State: Zip: Phone (circle 1) home / cell / work: Marital Status: Single / Married / Divorced / Widowed Work Status: Employed

More information

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

ANTI-DEPRESSANT MEDICATIONS

ANTI-DEPRESSANT MEDICATIONS ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change

More information

What do you believe is causing your most important health concern?

What do you believe is causing your most important health concern? Intake form Name Today s Date Date of Birth Address City Phone Postal Code Email Primary Health Care Provider Emergency Contact Phone Note: By providing your email address you are giving us consent to

More information

CSP Nabumetone ES/H/PSUR/0014/001. January 2010

CSP Nabumetone ES/H/PSUR/0014/001. January 2010 CSP Nabumetone ES/H/PSUR/0014/001 January 2010 CLINICAL PARTICULARS 4.1 Therapeutic indications Nabumetone is indicated in the symptomatic treatment of a variety of musculoskeletal disorders requiring

More information

OXYSPAS Tablets (Oxybutynin chloride)

OXYSPAS Tablets (Oxybutynin chloride) Published on: 10 Jul 2014 OXYSPAS Tablets (Oxybutynin chloride) Composition OXYSPAS-2.5 Tablets Each uncoated tablet contains Oxybutynin chloride... 2.5 mg OXYSPAS-5 Tablets Each uncoated tablet contains

More information

4.4 Special warnings and precautions for use

4.4 Special warnings and precautions for use SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Pregabalin Sandoz 25 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 25 mg of pregabalin.

More information

Continence PGD transdermal oxybutynin Kentera patch 36mg

Continence PGD transdermal oxybutynin Kentera patch 36mg Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence

More information

0BCore Safety Profile

0BCore Safety Profile 0BCore Safety Profile Active substance: Somatropin Pharmaceutical form(s)/strength: Powder and solvent for solution for injection, 4mg/ml, 5 mg/ml and 10 mg/ml P-RMS: FR/H/PSUR/0059/001 Date of FAR: 25.02.2013

More information

GLUCOSE TESTING-BLOOD

GLUCOSE TESTING-BLOOD Abnormal glucose tolerance complicating pregnancy, childbirth or the 648.83 puerperium, antepartum condition or complication Abnormal glucose tolerance complicating pregnancy, childbirth or the 648.84

More information